Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 16/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987547 | 1.00 | GLS (0.75) | GLSLMNAMAPTGAAHTT | |
| SCHEMBL16305174 | 0.93 | GLS (0.80) | GLSLMNAMAPT | |
| SCHEMBL15042339 | 0.93 | GLS (0.80) | GLSLMNAMAPT | |
| SCHEMBL18137256 | 0.91 | GLS (0.63) | GLSLMNAMAPTGAAHTT | |
| SCHEMBL21369057 | 0.88 | GLS (0.71) | GLSLMNAMAPT | |
| SCHEMBL17087141 | 0.86 | GLS (0.74) | GLS | |
| SCHEMBL14987541 | 0.86 | GLS (1.00) | GLS | |
| SCHEMBL16305175 | 0.84 | GLS (0.65) | GLSLMNAMAPTGAAHTT | |
| SCHEMBL14987621 | 0.84 | GLS (0.65) | GLSLMNAMAPTGAAHTT | |
| SCHEMBL15042275 | 0.83 | GLS (1.00) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | LIANG YU (US) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885LMNA 4498/4885MAPT 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.